Monopar Therapeutics (MNPR) to Release Earnings on Friday

Key Points

• Monopar Therapeutics is scheduled to release its earnings report on Friday, August 8th, with analysts predicting a loss of ($0.47) per share for the quarter.
• In its previous earnings report on May 13th, the company exceeded expectations by reporting a loss of ($0.38) EPS, beating the consensus estimate of ($0.65).
• CEO Chandler Robinson and Director Christopher M. Starr recently sold shares of Monopar, indicating a significant decrease in their holdings.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Monopar Therapeutics to post earnings of ($0.47) per share for the quarter.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.27. On average, analysts expect Monopar Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Monopar Therapeutics Stock Down 1.9%

Shares of MNPR traded down $0.76 during midday trading on Monday, reaching $39.93. 9,532 shares of the stock were exchanged, compared to its average volume of 40,416. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a 50 day simple moving average of $37.43 and a 200-day simple moving average of $37.72. The company has a market cap of $244.17 million, a price-to-earnings ratio of -11.57 and a beta of 1.05.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald started coverage on Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 price target for the company. Finally, Chardan Capital started coverage on Monopar Therapeutics in a report on Monday, June 23rd. They set a "buy" rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Monopar Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $60.00.

Insider Activity

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the transaction, the director owned 11,486 shares of the company's stock, valued at approximately $459,440. This represents a 43.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director directly owned 5,173 shares in the company, valued at approximately $206,920. This represents a 76.46% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,504 shares of company stock valued at $1,700,160. Insiders own 20.50% of the company's stock.

Institutional Trading of Monopar Therapeutics

An institutional investor recently bought a new position in Monopar Therapeutics stock. Goldman Sachs Group Inc. bought a new stake in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 18,480 shares of the company's stock, valued at approximately $673,000. Goldman Sachs Group Inc. owned about 0.30% of Monopar Therapeutics as of its most recent SEC filing. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.